Disease · MONDO_0000607
Trials145
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 145
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | Phase 3 | 372 | 2019-04-11 | Cutaneous T-Cell Lymphoma | MOGAMULIZUMAB, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02663518 | A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | Phase 1 | 249 | 2024-05-10 | Hematologic Malignancies, Solid Tumor | NIVOLUMAB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02448381 | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | Phase 3 | 169 | 2022-04-15 | Cutaneous T-Cell Lymphoma | HYPERICIN | Its record names the disease | ClinicalTrials.gov |
| NCT02581631 | An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas | Phase 1/2 | 145 | 2023-03-07 | Non-Hodgkin's Disease | BRENTUXIMAB VEDOTIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | Phase 2 | 139 | 2021-08-16 | Cutaneous T-Cell Lymphoma | PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00007345 | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | Phase 2 | 131 | 2016-02-12 | Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma | ROMIDEPSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01871727 | A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | Phase 3 | 112 | 2024-11-13 | Persistent or Recurrent Cutaneous T-Cell Lymphoma | DENILEUKIN DIFTITOX | Its record names the disease | ClinicalTrials.gov |
| NCT00106431 | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | 102 | 2010-04-23 | Cutaneous T-cell Lymphoma | ROMIDEPSIN | Its record names the disease | ClinicalTrials.gov |
| NCT03292406 | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | Phase 2 | 86 | 2021-04-08 | Cutaneous T Cell Lymphoma | RESIQUIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | Phase 4 | 59 | 2019-11-12 | Refractory Cutaneous T-cell Lymphoma | BEXAROTENE | Its record names the disease | ClinicalTrials.gov |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | Phase 1/2 | 58 | 2022-12-02 | Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor | DURVALUMAB, HILTONOL, TREMELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00542919 | A Study for Patients With Non-Hodgkin's Lymphomas | Phase 2 | 57 | 2020-10-19 | T-Cell Lymphoma, B-Cell Lymphoma | ENZASTAURIN | Its record names the disease | ClinicalTrials.gov |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | Phase 2 | 53 | 2014-10-27 | Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma | BELINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01456039 | A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) | Phase 1/2 | 51 | 2016-08-19 | Lymphoma, T-cell, Peripheral | ROMIDEPSIN | Its record names the disease | ClinicalTrials.gov |
| NCT00337987 | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma | Phase 2 | 49 | 2015-02-10 | Peripheral T-Cell Lymphoma | CYCLOPHOSPHAMIDE, DENILEUKIN DIFTITOX, DOXORUBICIN, PREDNISONE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02676778 | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma | Phase 2 | 45 | 2021-07-15 | Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | DENILEUKIN DIFTITOX | Its record names the disease | ClinicalTrials.gov |
| NCT00888927 | Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma | Phase 1/2 | 42 | 2020-12-29 | Peripheral T-Cell Lymphoma | MOGAMULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00255801 | Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma | Phase 2 | 37 | 2018-08-16 | Lymphoma | BEXAROTENE, DOXORUBICIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides | Phase 2 | 37 | 2022-04-08 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | COBOMARSEN, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00506129 | Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | Phase 2 | 33 | 2020-12-29 | Lymphoma, Disorder Related to Bone Marrow Transplantation | FLUDARABINE, MELPHALAN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000607/trials